Filtered By:
Source: Clinical Cancer Research
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 104 results found since Jan 2013.
Pan-cancer analysis of the Mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer.
CONCLUSIONS: Our analysis revealed distinct transcriptional expression profiles of the Mediator complex across cancer entities indicating differential modes of transcriptional regulation. Moreover it identified CDK19 and CDK8 to be specifically overexpressed during PCa progression, highlighting their potential as novel therapeutic targets in advanced PCa.
PMID: 27678455 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 26, 2016 Category: Cancer & Oncology Authors: Brägelmann J, Klümper N, Offermann A, von Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I, Merseburger AS, Vogel W, Sievers E, Vlasic I, Carlsson J, Andrén O, Brossart P, Duensing S, Svensson MA, Shaikhibrahim Z, Kirfel J, Perner S Tags: Clin Cancer Res Source Type: research
Overexpression of functional SLC6A3 in clear cell renal cell carcinoma.
CONCLUSIONS: We conclude that the dopamine transporter SLC6A3 constitute a novel biomarker that is highly specific for ccRCC. We further postulate that the protein can be exploited for diagnostic or therapeutic purposes for detection or treatment of ccRCC.
PMID: 27663598 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 22, 2016 Category: Cancer & Oncology Authors: Hansson J, Lindgren D, Nilsson H, Johansson E, Johansson M, Gustavsson L, Axelson H Tags: Clin Cancer Res Source Type: research
Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition.
CONCLUSIONS: These findings suggest a specific dependency of CCNE1 amplified tumors for AKT activity, and point to a novel combination of dinaciclib and AKT inhibitors that may selectively target patients with CCNE1 amplified HGSC.
PMID: 27663592 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 22, 2016 Category: Cancer & Oncology Authors: Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD Tags: Clin Cancer Res Source Type: research
Exportin-5 functions as an oncogene and a potential therapeutic target in colorectal cancer.
CONCLUSION: XPO5 acts like an oncogene in CRC by regulating the expression of miRNAs and may be a potential therapeutic target in CRC.
PMID: 27553833 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - August 22, 2016 Category: Cancer & Oncology Authors: Shigeyasu K, Okugawa Y, Toden S, Boland CR, Goel A Tags: Clin Cancer Res Source Type: research
MAPK Pathway Inhibitors Sensitize BRAF Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
CONCLUSIONS: The combination of MAPK pathway inhibitors with an antibody-drug-conjugate targeting GPNMB is an effective therapeutic option for patients with melanoma.
PMID: 27515299 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - August 10, 2016 Category: Cancer & Oncology Authors: Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong LN, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM Tags: Clin Cancer Res Source Type: research
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy.
CONCLUSIONS: VAC14 should be prioritized for further validation of its potential role as a predictor of docetaxel-induced neuropathy and biomarker for treatment individualization.
PMID: 27143689 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 2, 2016 Category: Cancer & Oncology Authors: Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel JN, Halabi S, Furukawa Y, Wheeler HE, Sibley A, Lassiter C, Weisman LS, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz D, Friedman PN, Mahoney JF, Carducci MA, Ke Tags: Clin Cancer Res Source Type: research
Trop-2 induces tumor growth through Akt and determines sensitivity to Akt inhibitors.
CONCLUSION: Our findings indicate that the expression of Trop-2 is a stringent predictor of tumor response to Akt inhibitors. They also support the identification of target-activatory pathways, as efficient predictors of response in precision cancer therapy.
PMID: 27022065 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 27, 2016 Category: Cancer & Oncology Authors: Guerra E, Trerotola M, Tripaldi R, Aloisi AL, Simeone P, Sacchetti A, Relli V, D' Amore A, La Sorda R, Lattanzio R, Piantelli M, Alberti S Tags: Clin Cancer Res Source Type: research
Cervical cancer stem cells selectively overexpress HPV oncoprotein E6 that controls stemness and self renewal through upregulation of HES1.
CONCLUSIONS: Our findings suggest the possible mechanism by which HPVE6 potentially regulate and maintain stem-like cancer cells through Hes1.
PMID: 26988248 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 17, 2016 Category: Cancer & Oncology Authors: Das BC, Tyagi A, Vishnoi K, Mahata S, Verma G, Srivastava Y, Masaldan S, Roy BG, Bharti AC Tags: Clin Cancer Res Source Type: research
Neddylation Inhibition Activates the Extrinsic Apoptosis Pathway through ATF4-CHOP-DR5 Axis in Human Esophageal Cancer Cells.
CONCLUSION: Our findings highlight a critical role of ATF4-CHOP-DR5 axis-mediated extrinsic apoptosis in neddylation-targeted cancer therapy and support the clinical investigation of neddylation inhibitors (e.g. MLN4924) for the treatment of ESCC, a currently treatment-resistant disease with neddylation hyperactivation.
PMID: 26983464 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 16, 2016 Category: Cancer & Oncology Authors: Chen P, Hu T, Liang Y, Li P, Chen X, Zhang J, Ma Y, Hao Q, Wang J, Zhang P, Zhang Y, Zhao H, Yang S, Yu J, Jeong LS, Qi H, Yang M, Hoffman RM, Dong Z, Jia L Tags: Clin Cancer Res Source Type: research
STAT3/5 dependent IL-9 overexpression contributes to neoplastic cell survival in mycosis fungoides.
CONCLUSIONS: Our results suggest that IL-9 and its regulators are promising new targets for therapy development in MF.
PMID: 26851186 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 5, 2016 Category: Cancer & Oncology Authors: Vieyra-Garcia PA, Wei T, Gram Naym D, Fredholm S, Fink-Puches R, Cerroni L, Odum N, O'Malley JT, Gniadecki R, Wolf P Tags: Clin Cancer Res Source Type: research
T-cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T cell Exhaustion and Poor Clinical Outcome in AML Patients.
CONCLUSION: TIGIT contributes to functional T cell impairment and associates with poor clinical outcome in AML. Our study suggests that blockade of TIGIT to restore T cell function and antitumor immunity may represent a novel effective leukemia therapeutic.
PMID: 26763253 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 13, 2016 Category: Cancer & Oncology Authors: Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka W, George MR, Zeng H, Zheng H Tags: Clin Cancer Res Source Type: research
Epigenetic regulation of the homeobox gene MSX1 associates with platinum resistant disease in high grade serous epithelial ovarian cancer.
CONCLUSIONS: Hypomethylation of CpG sites within the MSX1 gene is associated with resistant HGSOC disease at presentation and identifies expression of MSX1 as conferring platinum drug sensitivity.
PMID: 26763252 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 13, 2016 Category: Cancer & Oncology Authors: Bonito NA, Borely J, Wilhelm-Benartzi C, Ghaem-Maghami S, Brown R Tags: Clin Cancer Res Source Type: research
The landscape of prognostic outlier genes in high-risk prostate cancer.
CONCLUSIONS: To our knowledge, this study represents the first unbiased high-throughput investigation of prognostic outlier genes in prostate cancer and demonstrates the potential biomarker and therapeutic importance of this previously unstudied class of cancer genes.
PMID: 26631616 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - December 2, 2015 Category: Cancer & Oncology Authors: Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, Nguyen PL, Davicioni E, Feng FY Tags: Clin Cancer Res Source Type: research
Dysregulation of microRNA-212 Promotes Castration Resistance via hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer.
CONCLUSIONS: Our findings define novel roles for hnRNPH1 as a putative oncogene, splicing factor and an auxiliary AR coregulator. Targeted disruption of the hnRNPH1-AR axis may have therapeutic implications to improve clinical outcomes in patients with advanced PC, especially among AA-men.
PMID: 26553749 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - November 9, 2015 Category: Cancer & Oncology Authors: Yang Y, Jia D, Kim H, Abd Elmageed ZY, Datta A, Davis R, Srivastav S, Moroz K, Crawford B, Moparty K, Thomas R, Hudson RS, Ambs S, Abdel-Mageed AB Tags: Clin Cancer Res Source Type: research
Loss of glycogen debranching enzyme AGL drives bladder tumor growth via induction of hyaluronic acid synthesis.
CONCLUSIONS: Our study establishes HAS2 mediated HA synthesis as a driver of growth of bladder cancer with low AGL and provides preclinical rationale for personalized targeting of HAS2/HA signaling in patients with low AGL expressing tumors.
PMID: 26490312 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 21, 2015 Category: Cancer & Oncology Authors: Guin S, Ru Y, Agarwal N, Ritterson Lew C, Owens C, Comi GP, Theodorescu D Tags: Clin Cancer Res Source Type: research
